IPSEN

ipsen-logo

Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. The company markets approximately 20 drugs. It offers pharmaceutical products targeting oncology, endocrinology, and neuromuscular disorders, as well as gastroenterology, cardiovascular, and cognitive disorders. Products The company's products include: Decapeptyl is a peptide formulation for injection used to treat advanced prostate cancer. Somatuline and Somatuline Autogel is a sustained... -release formulations for injection of a somatostatin analogue peptide for treating acromegaly. NutropinAq is a liquid formulation for daily use of recombinant human growth hormone used in the treatment of growth failures. Increlex is a recombinant human Insulin-like Growth-Factor-1 for normal growth of bones. Dysport acts to block acetylcholine release for the treatment of motor disorders and various forms of muscular spasticity, including cervical dystonia. Smecta is an oral formulation of pharmaceutical clay used for the treatment of chronic and acute diarrhea in adults and children and in the symptomatic treatment of pain associated with esophageal, gastric, duodenal, or colonic disorders. Forlax is used for the treatment of constipation for adults and children. Tanakan is an oral formulation of EGb 761, extracted from the leaves of the Gingko biloba tree, is used in the treatment of age-related cognitive disorders. As of December 31, 2007, Tanakan is approved for use in approximately 60 countries, including Europe and Asia. Adrovance is used for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D deficiency. Adenuric is used for the treatment of chronic hyperuricaemia. Nisis and Nisisco is an oral formulations containing valsartan for treating arterial hypertension. Significant Events On June 15, 2009, Ipsen S.A. and Pharnext SAS announced that they have entered into an exclusive research, development and marketing agreement regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth disease, issued from the Pleotherapy technology. History Ipsen S.A. was founded in 1929.

#SimilarOrganizations #People #Financial #Event #Website #More

IPSEN

Social Links:

Industry:
Biotechnology Pharmaceutical Product Research

Founded:
1929-01-01

Address:
Boulogne-billancourt, Ile-de-France, France

Country:
France

Website Url:
http://www.ipsen.com

Total Employee:
1001+

Status:
Active

Contact:
(331) 583-3500

Email Addresses:
[email protected]

Total Funding:
22 M GBP

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network Domain Not Resolving Apache


Similar Organizations

active-biotech-logo

Active Biotech

Active Biotech is a company with focus on research and development of pharmaceutical products

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

bayer-logo

Bayer

Bayer offers prescription products primarily for cardiology and womenโ€™s health care; specialty therapeutics in the areas of oncology.

bioinvent-logo

BioInvent

BioInvent is a research-based pharmaceutical company.

glaxosmithkline-logo

GlaxoSmithKline

GlaxoSmithKline develops and markets products in the areas of pain relief, respiratory, digestive health, oral health, nutrition and skin.

organobalance-gmbh-logo

OrganoBalance GmbH

OrganoBalance GmbH develops, produces, and markets medicines used in the treatment of dental and skin bacterial infections.

phase-holographic-imaging-logo

Phase Holographic Imaging

Phase Holographic Imaging provides time-lapse cytometers for cancer and stem cell researchers in Europe, Asia, and North America.

reaction-biology-logo

Reaction Biology

Reaction Biology is an industry leader and innovator specializing in assay services and protein production for early-stage drug discovery

simbec-orion-group-logo

Simbec-Orion Group

Simbec-Orion Group Provides Clinical Development Solutions.

vertex-pharmaceuticals-logo

Vertex Pharmaceuticals

Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.


Current Advisors List

saran-muthiah_image

Saran Muthiah Scientific Advisory Board @ Ipsen
Advisor
2019-06-01

paul-sekhri_image

Paul Sekhri Board Director @ Ipsen
Board_member
2018-06-01

marc-de-garidel_image

Marc de Garidel Chairman @ Ipsen
Board_member
2016-07-01

joรซl-richard_image

JoรซL Richard Senior Director, Head of Drug Product Development @ Ipsen
Board_member
2008-08-01

michele-ollier_image

Michele Ollier Member of the Board of Directors @ Ipsen
Board_member

eric-ducamp_image

Eric Ducamp Senior Director, Head of Regulatory Analytics & Intelligence @ Ipsen
Board_member
2020-09-01

Current Employees Featured

elisabeth-vey_image

Elisabeth Vey
Elisabeth Vey Analytical Development Leader @ Ipsen
Analytical Development Leader

philippe-lopes-fernandes_image

Philippe Lopes-Fernandes
Philippe Lopes-Fernandes Executive Vice President, Chief Business Officer, Member of the Executive Committee @ Ipsen
Executive Vice President, Chief Business Officer, Member of the Executive Committee
2020-10-01

paul-murasko_image

Paul Murasko
Paul Murasko Head of Digital Customer Interaction for North America @ Ipsen
Head of Digital Customer Interaction for North America
2020-01-01

dominique-brard_image

Dominique Brard
Dominique Brard Executive Vice President, Human Resources @ Ipsen
Executive Vice President, Human Resources

tim-bourque_image

Tim Bourque
Tim Bourque Associate Director of Warehousing & Logistics @ Ipsen
Associate Director of Warehousing & Logistics
2017-04-01

christophe-jean_image

Christophe Jean
Christophe Jean Executive Vice President, Strategy and Business Development @ Ipsen
Executive Vice President, Strategy and Business Development

steven-hildemann_image

Steven Hildemann
Steven Hildemann EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs @ Ipsen
EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs
2020-03-01

stewart-campbell_image

Stewart Campbell
Stewart Campbell Executive Vice President & President of North America @ Ipsen
Executive Vice President & President of North America
2021-11-01

not_available_image

Antoine Flochel
Antoine Flochel Directors @ Ipsen
Directors

nigel-pitt_image

Nigel Pitt
Nigel Pitt Senior Chemical and Process Development Chemist @ Ipsen
Senior Chemical and Process Development Chemist

Founder


henri-beaufour_image

Henri Beaufour

Stock Details


Company's stock symbol is EPA:IPN

Acquisitions List

Date Company Article Price
2022-06-27 Epizyme Epizyme acquired by Ipsen 247 M USD
2019-02-25 Clementia Pharmaceuticals Clementia Pharmaceuticals acquired by Ipsen 1.3 B USD
2017-04-03 Merrimack Pharmaceuticals - Assets Merrimack Pharmaceuticals - Assets acquired by Ipsen N/A
2015-06-30 OctreoPharm Sciences OctreoPharm Sciences acquired by Ipsen 50 M EUR
2015-02-27 Canbex Therapeutics Canbex Therapeutics acquired by Ipsen 96 M EUR
2013-07-15 Syntaxin Syntaxin acquired by Ipsen 206 M USD
2008-07-05 Ipsen Pharmaceuticals, Inc. Ipsen Pharmaceuticals, Inc. acquired by Ipsen 17.5 M USD
2008-06-05 Octagen Octagen acquired by Ipsen N/A
2008-06-04 Tercica Tercica acquired by Ipsen 373 M USD
2004-03-04 Sterix Ltd. Sterix Ltd. acquired by Ipsen N/A

Investments List

Date Company Article Money raised
2021-11-18 BAKX Therapeutics Ipsen investment in Series A - BAKX Therapeutics 25 M USD
2021-03-30 Pyxis Oncology Ipsen investment in Series B - Pyxis Oncology 152 M USD
2020-03-02 Xilio Therapeutics Ipsen investment in Series B - Xilio Therapeutics 100.5 M USD
2019-07-17 Pyxis Oncology Ipsen investment in Series A - Pyxis Oncology 22 M USD
2017-02-16 Rhythm Pharmaceuticals Ipsen investment in Venture Round - Rhythm Pharmaceuticals 41 M USD
2017-01-31 Akkadeas Pharma Ipsen investment in Funding Round - Akkadeas Pharma N/A
2015-08-13 Rhythm Metabolic Ipsen investment in Series A - Rhythm Metabolic 40 M USD
2014-02-24 Thesan Pharmaceuticals Ipsen investment in Series B - Thesan Pharmaceuticals 49 M USD
2012-11-27 Motus Therapeutics Ipsen investment in Series B - Motus Therapeutics 8 M USD
2012-06-13 Motus Therapeutics Ipsen investment in Series B - Motus Therapeutics 25 M USD

Newest Events participated

smit-congress-2019_event_image Participated in SMIT CONGRESS 2019 on 2019-10-10 as exhibitor

clinical-operations-strategy-meeting-europe-2018_event_image Participated in Clinical Operations Strategy Meeting Europe 2018 on 2018-05-23 as speaker

medicinal-chemistry-strategy-meeting-europe-2018_event_image Participated in Medicinal Chemistry Strategy Meeting Europe 2018 on 2018-03-06 as speaker

Key Employee Changes

Date New article
2021-11-03 Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
2021-10-11 Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
2020-09-25 Ipsen names Philippe Lopes-Fernandes as EVP, chief business officer
2020-01-14 Ipsen recruits Steven Hildemann as CMO; Eli Lilly offers two more low-cost insulin options
2019-12-18 Ipsen Announces Departure of David Meek as Chief Executive Officer

Official Site Inspections

http://www.ipsen.com Semrush global rank: 1.07 M Semrush visits lastest month: 30.91 K

  • Host name: server-3-162-112-35.iad61.r.cloudfront.net
  • IP address: 3.162.112.35
  • Location: Seattle United States
  • Latitude: 47.6348
  • Longitude: -122.3451
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98109

Loading ...

More informations about "Ipsen" on Search Engine